IMC Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Immuron Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.076 |
| 52 Week High | AU$0.17 |
| 52 Week Low | AU$0.065 |
| Beta | 1.17 |
| 11 Month Change | -2.56% |
| 3 Month Change | -27.62% |
| 1 Year Change | 1.33% |
| 33 Year Change | -36.67% |
| 5 Year Change | -43.70% |
| Change since IPO | -59.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 1.3% | -0.3% | 0.9% |
| 1Y | 1.3% | 11.0% | 18.4% |
Return vs Industry: IMC underperformed the Australian Biotechs industry which returned 11% over the past year.
Return vs Market: IMC underperformed the Australian Market which returned 18.4% over the past year.
Price Volatility
| IMC volatility | |
|---|---|
| IMC Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: IMC has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: IMC's weekly volatility has decreased from 19% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 7 | Steve Lydeamore | www.immuron.com.au |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.
Immuron Limited Fundamentals Summary
| IMC fundamental statistics | |
|---|---|
| Market cap | AU$17.19m |
| Earnings (TTM) | -AU$6.94m |
| Revenue (TTM) | AU$4.90m |
3.5x
P/S Ratio-2.5x
P/E RatioIs IMC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMC income statement (TTM) | |
|---|---|
| Revenue | AU$4.90m |
| Cost of Revenue | AU$1.57m |
| Gross Profit | AU$3.34m |
| Other Expenses | AU$10.27m |
| Earnings | -AU$6.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.03 |
| Gross Margin | 68.06% |
| Net Profit Margin | -141.49% |
| Debt/Equity Ratio | 0% |
How did IMC perform over the long term?
See historical performance and comparison